Artemisinin resistance is rising in East Africa—leaving anti-malarials at risk of failure

AI Summary

Research by Imperial College London reveals rising artemisinin resistance in East Africa, threatening the efficacy of front-line malaria treatments. This development could undermine current anti-malarial therapies if resistance continues to expand.

Resistance to the main drug in front-line malaria treatments is becoming more widespread across East Africa, according to new research by Imperial College London. The study, published in The Lancet Infectious Diseases, maps the rise in artemisinin resistance in the region and suggests one of the safeguards built into these treatments is being eroded. The researchers warn that their findings raise the risk that the effectiveness of current treatments could decline over time if resistance continues to spread.